Multiple sclerosis (Houndmills, Basingstoke, England) | 6 Mar 2013
T Olsson, A Achiron, L Alfredsson, T Berger, D Brassat, A Chan, G Comi, M Eraksoy, H Hegen, J Hillert, PE Jensen, L Moiola, KM Myhr, A Oturai, S Schippling, A Siva, PS Sorensen, AK Trampe, T Weber, J Potts, T Plavina, D Paes and M Subramanyam
JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.
* Data courtesy of Altmetric.com